MIST MILESTONE PHARMACEUTICALS IN revenue, earnings and financials
For the quarter ended June 30, 2026, MILESTONE PHARMACEUTICALS IN reported revenue of $559K, net income of −$28.6M and diluted EPS of −$0.21; for the fiscal year ended December 2025 revenue was n/a.
MIST annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$62.1M, net income −$63.1K (margin n/a), EPS −$0.75
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$42.1M, net income −$41.5K (margin n/a), EPS −$0.67
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$61.1M, net income −$59.7K (margin n/a), EPS −$1.39
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$59.6M, net income −$58.4M (margin n/a), EPS −$1.38
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$43.1M, net income −$42.9M (margin n/a), EPS −$1.02
MIST quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $559K, net income −$28.6M, EPS −$0.21
- Quarter ended Mar 31, 2026: revenue $238K, net income −$26.1M, EPS −$0.20
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $45.6M, EPS −$0.12
- Quarter ended Sep 30, 2025: revenue n/a, net income −$11.9M, EPS −$0.12
- Quarter ended Jun 30, 2025: revenue $0, net income −$13.0M, EPS −$0.20
- Quarter ended Mar 31, 2025: revenue $0, net income −$20.8M, EPS −$0.31
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $29.1M, EPS −$0.18
- Quarter ended Sep 30, 2024: revenue n/a, net income −$9.44M, EPS −$0.14
- Quarter ended Jun 30, 2024: revenue n/a, net income −$9.36M, EPS −$0.14
- Quarter ended Mar 31, 2024: revenue n/a, net income −$10.4M, EPS −$0.21
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income $46.0M, EPS −$0.32
- Quarter ended Sep 30, 2023: revenue n/a, net income −$15.1M, EPS −$0.35
- Quarter ended Jun 30, 2023: revenue n/a, net income −$16.0M, EPS −$0.37
- Quarter ended Mar 31, 2023: revenue n/a, net income −$15.0M, EPS −$0.35
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$13.2M, EPS −$0.32
- Quarter ended Sep 30, 2022: revenue n/a, net income −$14.6M, EPS −$0.34
- Quarter ended Jun 30, 2022: revenue n/a, net income −$16.6M, EPS −$0.39
- Quarter ended Mar 31, 2022: revenue n/a, net income −$14.0M, EPS −$0.33
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$16.9M, EPS −$0.40
- Quarter ended Sep 30, 2021: revenue n/a, net income −$14.2M, EPS −$0.34
MIST cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$49.0M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$28.8M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$46.4M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$52.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$33.2M, share buybacks n/a
MIST balance sheet
- Jun 30, 2026: cash $170M, total assets $182M, total liabilities $163M, shareholders' equity $18.2M
- Mar 31, 2026: cash $71.3M, total assets $194M, total liabilities $158M, shareholders' equity $36.0M
- Dec 31, 2025: cash $73.0M, total assets $114M, total liabilities $71.8M, shareholders' equity $41.8M
- Sep 30, 2025: cash $46.7M, total assets $87.8M, total liabilities $67.2M, shareholders' equity $20.5M
- Jun 30, 2025: cash $42.5M, total assets $47.4M, total liabilities $65.2M, shareholders' equity −$17.7M
- Mar 31, 2025: cash $45.1M, total assets $61.9M, total liabilities $68.0M, shareholders' equity −$6.12M
- Dec 31, 2024: cash $25.3M, total assets $75.5M, total liabilities $62.4M, shareholders' equity $13.1M
- Sep 30, 2024: cash $12.8M, total assets $82.7M, total liabilities $58.7M, shareholders' equity $24.0M
Is MIST profitable?
No. MILESTONE PHARMACEUTICALS IN lost $21.0M over the last four quarters.
What is MIST's EPS?
Diluted earnings per share over the last four quarters were −$0.65; −$0.21 in the latest quarter.